The digitonin-permeabilized pancreatic islet model

Effect of *myo*-inositol 1,4,5-trisphosphate on Ca^{2+} mobilization

Bryan A. WOLF,* Patricia G. COMENS,* Karen E. ACKERMANN,† William R. SHERMAN†
and Michael L. McDANIEL*

*Department of Pathology and †Department of Psychiatry, Washington University School of Medicine,
St. Louis, MO 63110, U.S.A.

(Received 13 December 1984/14 February 1985; accepted 19 February 1985)

Glucose-induced insulin secretion is thought to be mediated by submicromolar increases in intracellular Ca^{2+} , although the intracellular processes are not well understood. We have used the previously characterized digitonin-permeabilized insulin-secreting pancreatic islet model to study the role of *myo*-inositol 1,4,5-trisphosphate (IP_3), a putative second messenger for mobilization of intracellular Ca^{2+} . Ca^{2+} efflux from the endoplasmic reticulum was studied with or without vanadate present to inhibit Ca^{2+} reuptake. IP_3 ($10\text{ }\mu\text{M}$), at a free Ca^{2+} level of $0.06\text{ }\mu\text{M}$, increased Ca^{2+} release by 30% and, when vanadate was present, by 50%. Maximal and half-maximal Ca^{2+} release was observed at $10\text{ }\mu\text{M}$ - and $2.5\text{ }\mu\text{M}$ - IP_3 , respectively. IP_3 provoked a rapid release that was followed by slow reuptake. Reuptake was diminished in the presence of vanadate. Inositol 1,4-bisphosphate, inositol 1-phosphate and other phosphoinositide metabolites did not have any significant effect. Because increases in Ca^{2+} levels in the submicromolar range have been previously shown to induce insulin release in digitonin-permeabilized islets, our results are consistent with the concept of IP_3 serving as a second messenger for insulin secretion.

Glucose is widely accepted as being the major stimulus for insulin secretion by the pancreatic β cell (Hedekov, 1980). However, the intracellular links between initiation and the final step of glucose-induced insulin secretion are not well known (McDaniel *et al.*, 1984). Intracellular Ca^{2+} is thought to be involved in the cellular control of insulin secretion (Wolheim & Sharp, 1981; McDaniel *et al.*, 1984). Recent studies have suggested that the endoplasmic reticulum has an important role in the regulation of intracellular Ca^{2+} (Colca *et al.*, 1983a, 1984). Furthermore, we have previously shown in the digitonin-permeabilized islet that increases of Ca^{2+} concentrations in the submicromolar range induce insulin secretion, possibly by activation of a particulate Ca^{2+} - and calmodulin-dependent protein kinase (Colca *et al.*, 1985).

It has been recently proposed that IP_3 , the product of agonist-induced phospholipase C hy-

drolysis of phosphatidylinositol 4,5-bisphosphate, could act as a second messenger for a wide variety of neurotransmitters and peptides by mobilization of intracellular Ca^{2+} (for reviews see Berridge, 1984, and Berridge & Irvine, 1984; see also Berridge *et al.*, 1984; Biden *et al.*, 1984; Burgess *et al.*, 1984; Gershengorn *et al.*, 1984; Hirata *et al.*, 1984; Irvine *et al.*, 1984; Joseph *et al.*, 1984). Several lines of evidence suggest that, in the β cell, glucose stimulates the metabolism of membrane phosphoinositides (Clements & Rhoten, 1976; Laychock, 1983; Dunlop & Larkins, 1984), with production of $[\text{^3H}]\text{IP}_3$ after incorporation of $[\text{^3H}]\text{inositol}$ into membrane phospholipids (Best & Malaisse, 1984). Ca^{2+} mobilization by IP_3 in non-tumour-derived insulin-secreting β cells is here shown by using digitonin-permeabilized islets (Colca *et al.*, 1985).

Experimental

Male Sprague–Dawley rats (200–300 g) were purchased from Sasco (O'Fallon, MO, U.S.A.). Collagenase (CLS IV) was obtained from Cooper

Abbreviations used: IP_3 , *myo*-inositol 1,4,5-trisphosphate; IP_2 , inositol 1,4-bisphosphate.

Biochemical (Freehold, NJ, U.S.A.), $^{45}\text{CaCl}_2$ (sp. radioactivity 800 mCi/mmol) and $^3\text{H}_2\text{O}$ were from New England Nuclear, the calcium ionophore A23187 was from Behring Diagnostics (La Jolla, CA, U.S.A.), and sodium vanadate was from Fisher Scientific Co. (Fair Lawn, NJ, U.S.A.); other chemicals, except as specified, were from Sigma.

Pancreatic islets were obtained after collagenase digestion and separation on a discontinuous Ficoll gradient (McDaniel *et al.*, 1983). Islets were then permeabilized with digitonin (Colca *et al.*, 1985).

Permeabilized islets (30/100 μl assay volume) were first loaded with 5 μCi of ^{45}Ca and with 5 μCi of $^3\text{H}_2\text{O}$ as a cell volume marker for 30 min at room temperature in a Tris buffer [50 mM-Tris/100 mM-KCl / 7 mM-MgCl₂ / 5 mM-ATP / 0.2 mM-EGTA (0.06 μM free Ca^{2+} , pH 7.2)]. The buffer also contained 5 μg of Ruthenium Red/ml to inhibit mitochondrial uptake. In some Ca^{2+} -efflux studies, vanadate (1.25 mM) was used to inhibit the reuptake of $^{45}\text{Ca}^{2+}$ by endoplasmic reticulum. ^{45}Ca content was expressed as pmol of Ca^{2+} /islet after correcting for cell volume and subtracting non-ATP-dependent Ca^{2+} diffusion.

Free Ca^{2+} concentrations were determined by using an apparent stability constant for Ca^{2+} -EGTA of $10^{6.85}$ (24°C, 100 mM-KCl, pH 7.2) which was determined from an absolute stability constant of $10^{10.97}$ (20°C, 1.0 M) by interpolating for temperature and the H^+ activity coefficient (Martell & Smith, 1974).

IP_3 and IP_2 were prepared from human polycythaemic red blood cells not over 2 weeks in age by using the method of Downes & Michell (1981) with modifications as follows. Ghosts were prepared from rejuvenated red cells (Shukla *et al.*, 1979) followed by washing in a continuous-flow filtration apparatus (Pellicon Cassette System; Millipore Corp., Bedford, MA, U.S.A.) (Rosenberry *et al.*, 1981). Ghosts from 6 units of blood were combined and treated with 2 mM- Ca^{2+} (37°C, 45 min) to release inositol phosphates from the phosphoinositides. The ghosts were then removed with the Pellicon system. The IP_2 and IP_3 were obtained from the filtrate (Downes & Michell, 1981), analysed by electrophoresis (Seiffert & Agranoff, 1965) and by g.l.c. (Sherman *et al.*, 1971; Agranoff & Seguin, 1974). Yields were approx. 6 μmol of IP_2 and 15 μmol of IP_3 /6 units of blood. D-Inositol 1-phosphate and DL-inositol cyclic 1,2-phosphate were prepared as described (Grado & Ballou, 1961; Sherman *et al.*, 1981).

Results

Characterization of Ca^{2+} uptake by the endoplasmic reticulum of digitonin-permeabilized islets

showed that this was an ATP-dependent process with maximal uptake occurring at 5 mM-ATP (range tested 0–10 mM; results not shown). This process was rapid; steady state occurred within the first 10 min and remained stable for 1 h (Fig. 1). The calcium ionophore A23187 (2 μM) induced a nearly total reversal of ATP-dependent Ca^{2+} uptake within 5 or 10 min (Fig. 1). Vanadate, a Ca^{2+} -ATPase inhibitor (Bond & Hudgins, 1980), was used during the efflux studies in order to

Fig. 1. Time course of ATP-dependent Ca^{2+} uptake by digitonin-treated pancreatic islets

Isolated islets were permeabilized with digitonin. In brief, islets were incubated for 20 min at 37°C in a modified Krebs buffer [115 mM-NaCl/5 mM-KCl/24 mM- NaHCO_3 /1 mM-MgCl₂/25 mM-Hepes (pH 6.8)/1 mM-EGTA/0.1% bovine serum albumin] with digitonin (20 $\mu\text{g}/\text{ml}$) and then washed three times in Tris buffer [50 mM-Tris (pH 6.8)/100 mM-KCl/5 mM-MgCl₂/0.1% bovine serum albumin]. Permeabilized islets (30/tube) were then loaded for the indicated time (0–60 min) with 5 μCi of ^{45}Ca , and with 5 μCi of $^3\text{H}_2\text{O}$ as a cell volume marker, at room temperature in a buffer mimicking intracellular conditions [50 mM-Tris (pH 6.8)/100 mM-KCl/7 mM-MgCl₂/5 mM-ATP/100 μM -CaCl₂] containing 5 μg of Ruthenium Red/ml. After 60 min loading time, efflux induced by calcium ionophore A23187 (2 μM) was measured after 5 and 10 min with ethanol as control (final concn. 5%). ^{45}Ca content of the endoplasmic reticulum was determined by centrifugation at 10000g for 1 min, aspiration of the supernatant, followed by dissolution of the islet pellet with 50 μl of Protosol and neutralization with 10 μl of acetic acid. Non-ATP-dependent Ca^{2+} uptake was determined separately for each experiment and, at each time, was subtracted from the data. Results are expressed as the means $\pm$ S.E.M. of ATP-dependent Ca^{2+} uptake (pmol/islet) for three experiments performed in triplicate.

Fig. 2. Effect of IP_3 on Ca^{2+} efflux (10 min) by digitonin-treated islets

Isolated islets were permeabilized with digitonin and loaded with 5 μCi of ^{45}Ca and 5 μCi of $^3\text{H}_2\text{O}$ as a cell volume marker for 30 min at room temperature in a Tris buffer mimicking intracellular conditions [50 mM-Tris (pH 7.2) 100 mM-KCl/7 mM- MgCl_2 /5 mM-ATP/0.2 mM-EGTA (0.06 μM free Ca^{2+})] containing 5 μg of Ruthenium Red/ml. Ca^{2+} efflux was then measured after 10 min in the presence or absence (water) of 10 μM - IP_3 with or without 1.25 mM-vanadate. Non-ATP-dependent Ca^{2+} uptake determined individually for each experiment was subtracted from the data. A23187 blanks were also subtracted from the relevant data. Results are shown as the means $\pm$ S.E.M. of ATP-dependent Ca^{2+} content (pmol/islet). Each group is the mean of 18 observations in three experiments.

minimize Ca^{2+} reuptake by the endoplasmic reticulum. The dose curve of vanadate inhibition of Ca^{2+} uptake showed that 50% inhibition was obtained for vanadate concentrations greater than 0.5 mM (range tested 0–5 mM; results not shown). The effects of efflux agents such as the calcium ionophore A23187 (2 μM) and EGTA (1 mM) were tested after 30 min loading time. Following 5 min exposure to these agents the percentage of Ca^{2+} released was similar with or without vanadate present (1.25 mM), indicating that vanadate did not interfere with efflux, although it did lower steady-state equilibrium level of Ca^{2+} .

The effect of IP_3 on Ca^{2+} efflux was studied at a free Ca^{2+} concentration of 0.06 μM , which is approximately half-maximal for Ca^{2+} -specific insulin secretion under these conditions (Colca *et al.*, 1985). As shown in Fig. 2, 10 μM - IP_3 induced a 30%

Fig. 3. Dose-response curve of IP_3 -induced Ca^{2+} release by digitonin-treated islets

Digitonin-permeabilized islets were loaded with Ca^{2+} as described for Fig. 2 and efflux was measured after 10 min in the presence of increasing concentrations of IP_3 (0–10 μM) and 1.25 mM-vanadate. Non-ATP-dependent Ca^{2+} uptake, determined individually for each experiment, was subtracted from the data. Results are expressed as the means $\pm$ S.E.M. of Ca^{2+} released (pmol/islet) from 18 observations from three experiments.

release ($P < 0.001$) of Ca^{2+} from permeabilized islets within 10 min. When 1.25 mM-vanadate was added during the efflux period to minimize Ca^{2+} reuptake, 10 μM - IP_3 induced a 50% efflux ($P < 0.001$) of Ca^{2+} , suggesting that vanadate was effectively inhibiting Ca^{2+} reuptake by the endoplasmic reticulum. The phosphoinositide metabolites IP_2 (10 μM), D-inositol 1-phosphate, DL-inositol cyclic 1,2-phosphate and *myo*-inositol (10 and 50 μM) had no significant effect on Ca^{2+} efflux with or without vanadate (results not shown; $n = 9$ –18) while IP_2 at 50 μM had a small Ca^{2+} -releasing effect. The dose curve of IP_3 on Ca^{2+} efflux showed dose dependency, with half-maximal release occurring at 2.5 μM - IP_3 and maximal Ca^{2+} release at 10 μM - IP_3 (Fig. 3). Time course studies of IP_3 -induced Ca^{2+} release are detailed in Fig. 4. IP_3 provoked maximal efflux of Ca^{2+} from the endoplasmic reticulum by 2 min, followed by slow reuptake. In the presence of vanadate, reuptake was diminished, suggesting that Ca^{2+} released by IP_3 from the endoplasmic reticulum is normally taken up by these same vesicles.

Discussion

The digitonin-permeabilized islet model was used to study Ca^{2+} efflux by the endoplasmic reticulum in the presence of Ruthenium Red which inhibits mitochondrial uptake. No further effect of IP_3 on Ca^{2+} release from the mitochondria was detected in the absence of Ruthenium Red. These data confirm that, in the pancreatic islet-cell, Ca^{2+} uptake by the endoplasmic reticulum is a rapid

Fig. 4. Time course of IP_3 -induced Ca^{2+} efflux by digitonin-treated islets

Digitonin-permeabilized islets were loaded with ^{45}Ca as described for Fig. 2 and efflux induced by IP_3 ($10\ \mu\text{M}$) was measured after 2, 5, 10, 20 and 30 min without (■) or with (●) 1.25 mM-vanadate. Non-ATP-dependent Ca^{2+} uptake determined individually for each experiment was subtracted from the data. A23187 blanks were also subtracted from the relevant data. Results are expressed as the means $\pm$ S.E.M. of Ca^{2+} content (pmol/islet) from three experiments in triplicate.

ATP-dependent process, reversed in the presence of the Ca^{2+} ionophore A23187 (Colca *et al.*, 1982). The validity of this permeabilized model for the study of insulin secretion as well as Ca^{2+} and calmodulin-dependent protein phosphorylation has also been reported (Colca *et al.*, 1985).

IP_3 caused specific Ca^{2+} release from the endoplasmic reticulum of islet cells. This effect was shown to be dependent on the intracellular Ca^{2+} concentration (levels tested $0.06\ \mu\text{M}$, $0.5\ \mu\text{M}$ and $100\ \mu\text{M}$): Ca^{2+} release could only be elicited at a Ca^{2+} concentration in the submicromolar range. This is a range similar to that for Ca^{2+} -induced insulin secretion (Colca *et al.*, 1985). The general characteristics of IP_3 -induced Ca^{2+} release from the endoplasmic reticulum of the pancreatic β cell are similar to those described for other tissues, i.e. rapid release that is followed by slow reuptake, although the IP_3 requirements differed among these tissues (see reviews by Berridge, 1984, and Berridge & Irvine, 1984). Our study gives further support for the role of IP_3 as a widely distributed second messenger for agonist-induced intracellular Ca^{2+} mobilization (Berridge, 1984; Berridge & Irvine, 1984).

Several groups have reported that glucose alters the metabolism of pancreatic islet phosphoinosi-

tides (Clements & Rhoten, 1976; Laychock, 1983; Dunlop & Larkins, 1984) with production of IP_3 (Best & Malaisse, 1984). The results reported here, taken with our previous study (Colca *et al.*, 1985), suggest that glucose-induced production of IP_3 leads to increased intracellular Ca^{2+} concentrations which are part of the sequence of events that lead to insulin secretion (see review by McDaniel *et al.*, 1984).

In the presence of vanadate, IP_3 -induced Ca^{2+} release was increased to 50%, in comparison with 30% in the absence of vanadate. Thus, the reuptake component of IP_3 -induced Ca^{2+} release is probably associated with the β cell endoplasmic reticulum Ca^{2+} -ATPase (Colca *et al.*, 1983b).

In conclusion, our results support a role for IP_3 as a second messenger for Ca^{2+} release from the endoplasmic reticulum of the β cell, and are consistent with an intracellular link between Ca^{2+} mobilization and insulin secretion.

We gratefully acknowledge the excellent technical assistance of C. Joan Fink, Deirdre Buscetto, Luigi Y. Munsell and Connie Marshall. These studies were supported in part by NIH grants AM03373, AM20579, and AM07296-06.

References

- Agranoff, B. W. & Seguin, E. B. (1974) *Prep. Biochem.* **4**, 359–366
- Berridge, M. J. (1984) *Biochem. J.* **220**, 345–360
- Berridge, M. J. & Irvine, R. F. (1984) *Nature (London)* **312**, 315–321
- Berridge, M. J., Heslop, J. P., Irvine, R. F. & Brown, K. D. (1984) *Biochem. J.* **222**, 195–201
- Best, L. & Malaisse, W. J. (1984) *Endocrinology (Baltimore)* **115**, 1814–1820
- Biden, T. J., Prentki, M., Irvine, R. F., Berridge, M. J. & Wolheim, C. B. (1984) *Biochem. J.* **223**, 467–473
- Bond, G. H. & Hudgins, P. M. (1980) *Biochim. Biophys. Acta* **600**, 781–790
- Burgess, G. M., McKinney, J. S., Irvine, R. F., Berridge, M. J., Hoyle, P. C. & Putney, J. W. (1984) *FEBS Lett.* **176**, 193–196
- Clements, R. S. & Rhoten, W. B. (1976) *J. Clin. Invest.* **57**, 684–691
- Colca, J. R., McDonald, J. M., Kotagal, N., Patke, C., Fink, C. J., Greider, M., Lacy, P. E. & McDaniel, M. L. (1982) *J. Biol. Chem.* **257**, 7223–7228
- Colca, J. R., Brooks, C. L., Landt, M. & McDaniel, M. L. (1983a) *Biochem. J.* **212**, 819–827
- Colca, J. R., Kotagal, N., Lacy, P. E. & McDaniel, M. L. (1983b) *Biochim. Biophys. Acta* **729**, 176–184
- Colca, J. R., Kotagal, N., Lacy, P. E., Brooks, C. L., Norling, L., Landt, M. & McDaniel, M. L. (1984) *Biochem. J.* **220**, 529–537
- Colca, J. R., Wolf, B. A., Comens, P. G. & McDaniel, M. L. (1985) *Biochem. J.*, in the press
- Downes, C. P. & Michell, R. H. (1981) *Biochem. J.* **198**, 133–140

- Dunlop, M. E. & Larkins, R. G. (1984) *J. Biol. Chem.* **259**, 8407–8411
- Gershengorn, M. C., Geras, E., Purrello, V. S. & Rebecchi, M. J. (1984) *J. Biol. Chem.* **259**, 10675–10681
- Grado, C. & Ballou, C. E. (1976) *J. Biol. Chem.* **236**, 54–60
- Hedekov, C. J. (1980) *Physiol. Rev.* **60**, 442–509
- Hirata, M., Suematsu, E., Hashimoto, T., Hamachi, T. & Koga, T. (1984) *Biochem. J.* **223**, 229–236
- Irvine, R. F., Brown, K. D. & Berridge, M. J. (1984) *Biochem. J.* **221**, 269–272
- Joseph, S. K., Williams, R. J., Corkey, B. E., Matschinsky, F. M. & Williamson, J. R. (1984) *J. Biol. Chem.* **259**, 12952–12955
- Laychock, S. G. (1983) *Biochem. J.* **216**, 101–106
- Martell, A. E. & Smith, R. M. (1974) *Critical Stability Constants Volume I: Amino Acids*, Plenum Press, New York
- McDaniel, M. L., Colca, J. R., Kotagal, N. & Lacy, P. E. (1983) *Methods Enzymol.* **98**, 182–200
- McDaniel, M. L., Colca, J. R., Kotagal, N. & Lacy, P. E. (1984) in *The Diabetic Pancreas* (Volk, B. W. & Arquilla, E. R., eds.), pp. 213–231, Plenum Press, New York
- Rosenberry, T. L., Chen, J. F., Lee, M. M. L., Moulton, T. A. & Onigman, P. (1981) *J. Biochem. Biophys. Methods* **4**, 39–48
- Seiffert, U. B. & Agranoff, B. W. (1965) *Biochim. Biophys. Acta.* **98**, 574–581
- Sherman, W. R., Goodwin, S. L. & Zinbo, M. (1971) *J. Chromatogr. Sci.* **9**, 363–367
- Sherman, W. R., Leavitt, A. C., Honchar, M. P., Hallcher, L. M. & Phillips, B. E. (1981) *J. Neurochem.* **36**, 1947–1951
- Shukla, S. D., Coleman, R., Finean, J. B. & Michell, R. H. (1979) *Biochem. J.* **179**, 441–444
- Wolheim, C. B. & Sharp, G. W. G. (1981) *Physiol. Rev.* **61**, 914–973